go-v.orgdoi

Prognostic Value Of hMLH1 and hMSH2 Immunohistochemical Expression In Non-Small Cell Lung Cancer

— · The Internet Journal of Pulmonary Medicine · 2006

  • DOI 10.5580/cc0
  • Publisher OpenAlex
  • Type article
  • Issued 2006

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

The Internet Journal of Pulmonary Medicine · OpenAlex · article · 2006

Abstract

Purpose and Experimental Design: The etiologic association and prognostic significance of mismatch repair gene/protein alterations have never been examined in lung cancer. We investigated protein expression of hMLH1 and hMSH2 genes in tumor specimens from 105 non–small cell lung cancer (NSCLC) patients. 60 of them were diagnosed with adenocarcinoma, 38 with squamous cell carcinoma and seven with large cell carcinoma. Out of the 105 patients 40 (20 adenocarcinomas and 20 squamous cell carcinomas) had already received neoadjuvant chemotherapy based on Carboplatine and navelbine or carboplatine vepesid. Immunohistochemical staining was used to examine protein expression.

Expression in each patient was compared with clinicopathologic variables as well as overall survival and cancer-specific survival rates. Results: Alteration of protein expression was observed in 30% of patients. Loss of hMLH1 and hMSH2 protein expression was associated with significantly shorter disease-free survival in patients who had received neoadjuvant chemotherapy (p=0.1). Conclusion: Loss of immunohistochemical expression of hMLH1 and hMSH2 markers in lung tumors indicates a poorer prognosis for NSCLC patients receiving neoadjuvant therapy.

Open the resolved locator · 10.5580/cc0

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-20 01:04 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
https://doi.org/10.5580/cc0
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.